Stockscreener 앱 받기
37.90
0.71%
-0.27
시간 외 거래:
37.84
-0.06
-0.16%
전일 마감가:
$38.17
열려 있는:
$38.33
하루 거래량:
225.36K
Relative Volume:
0.65
시가총액:
$2.62B
수익:
$751.00K
순이익/손실:
$-74.57M
주가수익비율:
-34.36
EPS:
-1.1031
순현금흐름:
$-55.52M
1주 성능:
+10.66%
1개월 성능:
+29.77%
6개월 성능:
+176.84%
1년 성능:
+148.52%
1일 변동 폭
$36.58
$38.33
1주일 범위
$33.52
$38.90
52주 변동 폭
$12.56
$38.90
펄스 바이오 Stock (PLSE) Company Profile
명칭
Pulse Biosciences Inc
전화
510-906-4600
주소
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, RMD, MDLN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
37.90 | 2.27B | 751.00K | -74.57M | -55.52M | -1.1031 |
ISRG
Intuitive Surgical Inc
|
375.20 | 127.84B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
170.66 | 43.79B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
70.57 | 32.81B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
224.03 | 29.46B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
36.66 | 33.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
펄스 바이오 Stock (PLSE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 개시 | Mizuho | Outperform |
| 2025-07-07 | 개시 | Oppenheimer | Outperform |
| 2021-07-27 | 개시 | Stephens | Overweight |
| 2021-03-11 | 개시 | Maxim Group | Buy |
| 2021-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-12 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | 개시 | H.C. Wainwright | Buy |
모두보기
펄스 바이오 주식(PLSE)의 최신 뉴스
Oppenheimer Adjusts Pulse Biosciences PT to $35 From $30, Maintains Outperform Rating - marketscreener.com
Oppenheimer raises Pulse Biosciences stock price target on AF data - Investing.com
Pulse Biosciences Inc (PLSE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pulse Biosciences Inc (PLSE) Cash Flow - TradingKey
PLSE|Pulse Biosciences Inc|Price:30.230|Chg%:-0.770 - TradingKey
TradingKey - TradingKey
Pulse Biosciences, Inc Revenue Breakdown – NASDAQ:PLSE - TradingView
This Little-Known Biotech Stock Just Hit a New 5-Year High - Yahoo Finance
Pulse Biosciences Inc (PLSE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pulse Biosciences stock hits 52-week high at 31.09 USD By Investing.com - Investing.com Australia
Pulse Biosciences stock hits 52-week high at 31.09 USD - Investing.com
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026 - Finviz
Pulse Biosciences to report Q2 2026 results on August 6 - scanx.trade
$Pulse Biosciences (PLSE.US)$ squeeze baby squeeze - Moomoo
Pulse Biosciences, Inc (PLSE) Stock Analysis: Unpacking The 5.89% Potential Upside - DirectorsTalk Interviews
PULSE BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) - Moomoo
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Liquidity Mapping Around (PLSE) Price Events - Stock Traders Daily
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - AOL.com
Pulse Biosciences stock stays tied to filings and financing - AD HOC NEWS
Why (PLSE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Did Warrant Redemptions Just Reframe Pulse Biosciences' (PLSE) Cardiac Ablation Investment Narrative? - Sahm
Price to earnings forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
PLSE Forecast — Price Target — Prediction for 2027 - TradingView
Pulse Biosciences Shares Tumble Over 5% as Bearish Momentum BuildsMonthly Profile - dars.gov.et
Price to sales forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Price to book forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Enterprise value to EBITDA forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Enterprise value to EBIT forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Price to book forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Enterprise value to revenue forward of Pulse Biosciences, Inc – NASDAQ:PLSE - TradingView
Enterprise value to revenue forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Price to sales forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Price to earnings forward of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Pulse Biosciences Inc (PLSE) Institutional Confidence - TradingKey
Pulse Biosciences stock hits 52-week high at $28.68 By Investing.com - Investing.com Nigeria
Pulse Biosciences stock hits 52-week high at $28.68 - Investing.com
Pulse Biosciences, Inc. Actuals & Estimates (NASDAQ:PLSE) - TradingView
Pulse Biosciences, Inc. Actuals & Estimates (FWB:6L8) - TradingView
Pulse Biosciences, Inc. Actuals & Estimates (DUS:6L8) - TradingView
6L8 Forecast — Price Target — Prediction for 2027 - TradingView
Pulse Biosciences Inc (PLSE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth - Moomoo
Pulse Biosciences Inc (PLSE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pulse Biosciences (PLSE) Is Up 5.0% After Joining S&P Healthcare Equipment Index Is Sentiment Shifting? - simplywall.st
Pulse Biosciences, Inc.(NasdaqCM:PLSE) added to S&P Healthcare Equipment Select Industry Index - marketscreener.com
Understanding Momentum Shifts in (PLSE) - Stock Traders Daily
Pulse Biosciences Stockweekly review and sector comparison - AD HOC NEWS
Pulse Biosciences Inc (PLSE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pulse Biosciences Strengthens Executive Team - Medical Product Outsourcing
Pulse Biosciences Inc (PLSE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
펄스 바이오 (PLSE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
펄스 바이오 주식 (PLSE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Director |
May 11 '26 |
Buy |
19.69 |
660,233 |
12,999,988 |
48,211,433 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Option Exercise |
1.53 |
5,000 |
7,650 |
48,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Sale |
23.63 |
20,000 |
472,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Sale |
23.53 |
20,000 |
470,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Sale |
23.37 |
20,000 |
467,400 |
43,298 |
0.90%
3.60%
자본화:
|
볼륨(24시간):